Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30685249 | 0.89 | OPRD1 (0.54) | OPRD1OPRM1OPRK1KISS1RSLC6A2 | |
| SCHEMBL30519203 | 0.86 | MME (0.54) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30845376 | 0.85 | NPY1R (0.56) | OPRD1OPRM1KISS1R | |
| SCHEMBL31542110 | 0.84 | BACE1 (0.46) | KISS1RCTSDBACE1 | |
| SCHEMBL30953201 | 0.84 | MME (0.47) | OPRD1OPRM1CTSDBACE1 | |
| SCHEMBL29350612 | 0.84 | ACE (0.58) | OPRD1OPRM1OPRK1SLC6A2 | |
| SCHEMBL31276527 | 0.84 | SLC7A5 (0.56) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29405922 | 0.83 | CTSD (0.61) | OPRD1OPRM1OPRK1CTSD | |
| SCHEMBL30900787 | 0.83 | OPRM1 (0.52) | OPRD1OPRM1KISS1RCTSD | |
| SCHEMBL29816805 | 0.83 | KISS1R (0.52) | OPRD1OPRM1OPRK1KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099172-A1 | SPHINGOLIPID BASED HAIR TREATMENT | SEDERMA (FR) | 2026-05-15 | — | — | WO | disclosed |
| EP-4489718-B1 | METHOD FOR ENCAPSULATING A HYDROPHOBIC COMPOUND, SUSPENSION OF STRUCTURED LIPID PARTICLES ACCORDING TO THIS METHOD, AND USES OF SAID SUSPENSION | SEDERMA SA (FR) | 2026-03-11 | — | — | EP | disclosed |
| EP-3518888-B1 | ALKYL-PHTALIDES FOR USE IN THE COSMETIC TREATMENT OF NAILS | SEDERMA SA (FR) | 2025-11-19 | — | — | EP | disclosed |
| EP-4076367-B1 | COSMETIC OR DERMATOLOGICAL COMPOSITION ACTING IN PARTICULAR ON THE EFFECTS OF BLUE LIGHT ON SKIN AND ITS APPENDAGES, AND ASSOCIATED USES | SEDERMA SA (FR) | 2025-11-19 | — | — | EP | disclosed |
| EP-4637797-A1 | METHOD FOR OBTAINING AN EXTRACT OF PLANT ORIGIN, A COMPOSITION CONTAINING IT AND ITS COSMETIC USE | SEDERMA (FR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4635974-A1 | COSMETIC COMPOSITION FOR SKIN IMPROVEMENT | LG Household & Health Care Ltd. (KR) | 2025-10-22 | — | — | EP | disclosed |
| US-12433835-B2 | Cosmetic composition and treatment for treating skin sagging | SEDERMA (FR) | 2025-10-07 | — | — | US | disclosed |
| EP-3655112-B1 | USE OF A BACTERIAL EXTRACT FOR A COSMETIC OR DERMATOLOGICAL TREATMENT, IN PARTICULAR A MOISTURIZING TREATMENT | SEDERMA SA (FR) | 2025-09-03 | — | — | EP | disclosed |
| EP-3746041-B1 | USE OF CYCLIC PEPTIDES IN COSMETIC | SEDERMA SA (FR) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025036736-A1 | EXOPOLYSACCHARIDE AND OLIGOSACCHARIDES IN PARTICULAR FOR COSMETICS | SEDERMA (FR) | 2025-02-20 | — | — | WO | disclosed |
| EP-4037656-A1 | USE OF LEONTODIUM ALPINUM PLANT CELLS FOR AN ANTI-GLYCATION ANTI-AGEING SKIN TREATMENT | SEDERMA (FR) | 2022-08-10 | — | — | EP | disclosed |
| CN-109789079-B | Topical weight loss cosmetic treatment | 赛德玛公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-109789080-B | Alkyl phthalides for use in cosmetic treatment of nails | 赛德玛公司 | 2022-06-24 | — | — | CN | disclosed |
| WO-2022106365-A1 | TETRAPEPTIDES, COMPOSITIONS COMPRISING THEM, AND THEIR COSMETIC USE | SEDERMA (FR) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106366-A1 | COSMETIC TETRAPEPTIDE, COMPOSITION AND USE | SEDERMA (FR) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106444-A1 | TETRAPEPTIDES, COMPOSITIONS COMPRISING THEM, AND THEIR COSMETIC USE | SEDERMA (FR) | 2022-05-27 | — | — | WO | disclosed |
| CN-114555045-A | Peptide-based cosmetic or dermatological treatment of skin and its appendages | 赛德玛公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114502140-A | Anti-aging cosmetic treatment for anti-saccharification effect of alpine edelweiss plant cells | 赛德玛公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-108778242-B | Cosmetic use of ingredients derived from marrubium vulgare | 赛德玛公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20220062139-A1 | TOPICAL COSMETIC TREATMENT OF SKIN AND SCALP AND CORRESPONDING ACTIVE INGREDIENT BASED ON AN EXTRACT OF APIUM GRAVEOLENS | SEDERMA (FR) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062139-A1 | TOPICAL COSMETIC TREATMENT OF SKIN AND SCALP AND CORRESPONDING ACTIVE INGREDIENT BASED ON AN EXTRACT OF APIUM GRAVEOLENS | SAP18, CYP51A1, NAA10 | OPRD1 1666/4885OPRM1 4724/4885OPRK1 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.